Immune Netw.  2017 Dec;17(6):410-423. 10.4110/in.2017.17.6.410.

Terminally Differentiating Eosinophils Express Neutrophil Primary Granule Proteins as well as Eosinophil-specific Granule Proteins in a Temporal Manner

Affiliations
  • 1Department of Bionano Engineering, Hanyang University, Ansan 15588, Korea. iychu@hanyang.ac.kr
  • 2Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea.
  • 3Department of Microbiology, Gachon University School of Medicine, Incheon 21936, Korea.
  • 4Department of Molecular and Life Sciences, Hanyang University, Ansan 15588, Korea.

Abstract

Neutrophils and eosinophils, 2 prominent granulocytes, are commonly derived from myelocytic progenitors through successive stages in the bone marrow. Our previous genome-wide transcriptomic data unexpectedly showed that genes encoding a multitude of neutrophil primary granule proteins (NPGPs) were markedly downregulated during the end period of eosinophilic terminal differentiation when cord blood (CB) cluster of differentiation (CD) 34+ cells were induced to differentiate toward the eosinophil lineage during a 24-day culture period. Accordingly, this study aimed to examine whether NPGP genes were expressed on the way to eosinophil terminal differentiation stage and to compare their expression kinetics with that of genes encoding eosinophil-specific granule proteins (ESGPs). Transcripts of all NPGP genes examined, including proteinase 3, myeloperoxidase, cathepsin G (CTSG), and neutrophil elastase, reached a peak at day 12 and sharply declined thereafter, while transcript of ESGP genes including major basic protein 1 (MBP1) attained maximum expression at days 18 or 24. Growth factor independent 1 (GFI1) and CCAAT/enhancer-binding protein α (C/EBPA), transactivators for the NPGP genes, were expressed immediately before the NPGP genes, whereas expression of C/EBPA, GATA1, and GATA2 kinetically paralleled that of eosinophil granule protein genes. The expression kinetics of NPGPs and ESGPs were duplicated upon differentiation of the eosinophilic leukemia cell line (EoL-1) immature eosinophilic cells. Importantly, confocal image analysis showed that CTSG was strongly coexpressed with MBP1 in differentiating CB eosinophils at days 12 and 18 and became barely detectable at day 24 and beyond. Our results suggest for the first time the presence of an immature stage where eosinophils coexpress NPGPs and ESGPs before final maturation.

Keyword

Cathepsin G; Cord blood; Eosinophils; Major basic protein 1; Neutrophils

MeSH Terms

Bone Marrow
Cathepsin G
Cell Line
Eosinophils*
Fetal Blood
Granulocytes
Hypereosinophilic Syndrome
Kinetics
Leukocyte Elastase
Myeloblastin
Neutrophils*
Peroxidase
Trans-Activators
Cathepsin G
Leukocyte Elastase
Myeloblastin
Peroxidase
Trans-Activators

Figure

  • Figure 1 mRNA levels of neutrophil- and eosinophil-specific genes during differentiation of CB CD34+ cells toward eosinophils. Expression of 14 genes was determined by real-time PCR. The results represent the mean±standard error of the mean from 3–4 donors in which each measurement was performed in triplicate (*p<0.05 and **p<0.01, compared with day 6 CB cells).

  • Figure 2 mRNA levels of neutrophil- and eosinophil-specific genes in EoL-1 eosinophilic cells. EoL-1 cells were induced to differentiate in the absence or presence of dbcAMP (0.1 mM) for 1 and 3 days. Transcript levels are expressed as fold increase relative to expression at day 1 in the absence of dbcAMP. The results represent the mean±standard error of the mean of 3 to 5 independent experiments. Each measurement was performed in triplicate (*p<0.05 and **p<0.01 for comparison between the absence and presence of dbcAMP on each day).

  • Figure 3 Immunofluorescence microscopy analysis of MBP1 and CTSG expression. (A) Differentiating CB cells at 4 different time points. Cells were stained with ALEXA488-anti-MBP1 (green) and rhodamine-anti-CTSG (red) antibodies. Fluorescence images were acquired using a ZEISS LSM 800 confocal microscope (ZEISS, Oberkochen, Germany), and their mean fluorescence intensities were analyzed in ten developing CB cells using ImageJ software (National Institutes of Health, Bethesda, MD, USA). These photos are representatives of developing CB cells from 3 donors (*p<0.01, compared with day 6 CB cells). (B, C) PB eosinophils (B) and neutrophils (C) were stained with the same Abs and visualized. The scale bars indicate 20 µm.

  • Figure 4 Western blot analysis of neutrophil-specific granule proteins and ESGPs. (A) CTSG, MPO, Olig2, and MBP1 proteins were analyzed in differentiating CB cells at 6, 12, 18, and 24 days. This result is representative of cultures of CB cells from 3 donors. (B) CTSG, MPO, and MBP1 proteins were evaluated in PB eosinophils (E) and neutrophils (N) purified from 3 donors. The anti-MPO Ab used cross-reacted weakly with EPX.


Reference

1. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012; 30:459–489.
Article
2. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006; 24:147–174.
Article
3. Willebrand R, Voehringer D. Regulation of eosinophil development and survival. Curr Opin Hematol. 2017; 24:9–15.
Article
4. Fiedler K, Brunner C. The role of transcription factors in the guidance of granulopoiesis. Am J Blood Res. 2012; 2:57–65.
5. Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, Uike N, Niiro H, Takenaka K, Nagafuji K, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 2009; 206:183–193.
Article
6. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997; 89:3503–3521.
Article
7. Borregaard N, Theilgaard-Mönch K, Sørensen OE, Cowland JB. Regulation of human neutrophil granule protein expression. Curr Opin Hematol. 2001; 8:23–27.
Article
8. Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood. 1992; 80:1725–1735.
Article
9. D’Alo’ F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P, Nerlov C, Tenen DG. The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. Blood. 2003; 102:3163–3171.
10. Gombart AF, Kwok SH, Anderson KL, Yamaguchi Y, Torbett BE, Koeffler HP. Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1. Blood. 2003; 101:3265–3273.
Article
11. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010; 33:657–670.
Article
12. Theilgaard-Mönch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, Nielsen FC, Cowland JB, Borregaard N. The transcriptional program of terminal granulocytic differentiation. Blood. 2005; 105:1785–1796.
Article
13. Hock H, Hamblen MJ, Rooke HM, Traver D, Bronson RT, Cameron S, Orkin SH. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity. 2003; 18:109–120.
Article
14. Dvorak AM, Letourneau L, Login GR, Weller PF, Ackerman SJ. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils. Blood. 1988; 72:150–158.
Article
15. Du J, Stankiewicz MJ, Liu Y, Xi Q, Schmitz JE, Lekstrom-Himes JA, Ackerman SJ. Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem. 2002; 277:43481–43494.
Article
16. Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res. 2012; 4:68–79.
Article
17. Hwang SM, Uhm TG, Lee SK, Kong SK, Jung KH, Binas B, Chai YG, Park SW, Chung IY. Olig2 is expressed late in human eosinophil development and controls Siglec-8 expression. J Leukoc Biol. 2016; 100:711–723.
Article
18. Uhm TG, Lee SK, Kim BS, Kang JH, Park CS, Rhim TY, Chang HS, Kim DJ, Chung IY. CpG methylation at GATA elements in the regulatory region of CCR3 positively correlates with CCR3 transcription. Exp Mol Med. 2012; 44:268–280.
Article
19. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9:671–675.
Article
20. Lee JJ, Jacobsen EA, Ochkur SI, McGarry MP, Condjella RM, Doyle AD, Luo H, Zellner KR, Protheroe CA, Willetts L, et al. Human versus mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red. J Allergy Clin Immunol. 2012; 130:572–584.
Article
21. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013; 70:3813–3827.
Article
22. Levi-Schaffer F, Lacy P, Severs NJ, Newman TM, North J, Gomperts B, Kay AB, Moqbel R. Association of granulocyte-macrophage colony-stimulating factor with the crystalloid granules of human eosinophils. Blood. 1995; 85:2579–2586.
Article
23. Nakajima T, Matsumoto K, Suto H, Tanaka K, Ebisawa M, Tomita H, Yuki K, Katsunuma T, Akasawa A, Hashida R, et al. Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. Blood. 2001; 98:1127–1134.
Article
24. Mayumi M. EoL-1, a human eosinophilic cell line. Leuk Lymphoma. 1992; 7:243–250.
Article
25. Wong CK, Ho CY, Lam CW, Zhang JP, Hjelm NM. Differentiation of a human eosinophilic leukemic cell line, EoL-1: characterization by the expression of cytokine receptors, adhesion molecules, CD95 and eosinophilic cationic protein (ECP). Immunol Lett. 1999; 68:317–323.
Article
26. Jung Y. Comparative analysis of dibutyric cAMP and butyric acid on the differentiation of human eosinophilic leukemia EoL-1 cells. Immune Netw. 2015; 15:313–318.
Article
27. Sakamaki K, Kanda N, Ueda T, Aikawa E, Nagata S. The eosinophil peroxidase gene forms a cluster with the genes for myeloperoxidase and lactoperoxidase on human chromosome 17. Cytogenet Cell Genet. 2000; 88:246–248.
Article
28. Sakamaki K, Tomonaga M, Tsukui K, Nagata S. Molecular cloning and characterization of a chromosomal gene for human eosinophil peroxidase. J Biol Chem. 1989; 264:16828–16836.
Article
29. Wilkerson EM, Johansson MW, Hebert AS, Westphall MS, Mathur SK, Jarjour NN, Schwantes EA, Mosher DF, Coon JJ. The peripheral blood eosinophil proteome. J Proteome Res. 2016; 15:1524–1533.
Article
30. Paul F, Arkin Y, Giladi A, Jaitin DA, Kenigsberg E, Keren-Shaul H, Winter D, Lara-Astiaso D, Gury M, Weiner A, et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. Cell. 2015; 163:1663–1677.
Article
31. Wong TW, Jelinek DF. Purification of functional eosinophils from human bone marrow. J Immunol Methods. 2013; 387:130–139.
Article
32. Dyer KD, Moser JM, Czapiga M, Siegel SJ, Percopo CM, Rosenberg HF. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol. 2008; 181:4004–4009.
Article
33. Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, McLeish KR. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics. 2005; 4:1503–1521.
Article
34. Liu Q, Dong F. Gfi-1 inhibits the expression of eosinophil major basic protein (MBP) during G-CSF-induced neutrophilic differentiation. Int J Hematol. 2012; 95:640–647.
Article
35. El Ouriaghli F, Fujiwara H, Melenhorst JJ, Sconocchia G, Hensel N, Barrett AJ. Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood. 2003; 101:1752–1758.
Article
36. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood. 1996; 88:761–777.
Article
Full Text Links
  • IN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr